Oscar Moradei

1.6k total citations
22 papers, 939 citations indexed

About

Oscar Moradei is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Oscar Moradei has authored 22 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Organic Chemistry and 3 papers in Oncology. Recurrent topics in Oscar Moradei's work include Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Oscar Moradei is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Oscar Moradei collaborates with scholars based in Argentina, Germany and United States. Oscar Moradei's co-authors include Arkadii Vaisburg, Zuomei Li, Jeffrey M. Besterman, Marie-Claude Trachy-Bourget, Marielle Fournel, Isabelle Paquin, Daniel Delorme, Jinru Wang, Jubrail Rahil and Sylvain Lefèbvre and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Oscar Moradei

22 papers receiving 904 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oscar Moradei Argentina 11 752 299 209 93 55 22 939
Michael F. T. Koehler United States 15 640 0.9× 231 0.8× 168 0.8× 116 1.2× 98 1.8× 21 936
Peter Kovar United States 19 612 0.8× 379 1.3× 261 1.2× 51 0.5× 16 0.3× 39 993
William C. Trenkle United States 12 387 0.5× 269 0.9× 53 0.3× 29 0.3× 67 1.2× 18 776
Sukumar Sakamuri United States 13 393 0.5× 330 1.1× 154 0.7× 116 1.2× 49 0.9× 24 724
Matthew G. Bursavich United States 17 504 0.7× 379 1.3× 106 0.5× 122 1.3× 13 0.2× 29 904
Peter Lassota United States 9 456 0.6× 136 0.5× 113 0.5× 174 1.9× 198 3.6× 12 730
Blaise Lippa United States 13 394 0.5× 427 1.4× 108 0.5× 195 2.1× 136 2.5× 22 771
Ivo Zemp Switzerland 16 971 1.3× 86 0.3× 163 0.8× 39 0.4× 23 0.4× 17 1.1k
Raul R. Calvo United States 16 615 0.8× 295 1.0× 309 1.5× 42 0.5× 62 1.1× 22 1.0k
Mary Pat Beavers United States 17 408 0.5× 192 0.6× 63 0.3× 39 0.4× 22 0.4× 25 729

Countries citing papers authored by Oscar Moradei

Since Specialization
Citations

This map shows the geographic impact of Oscar Moradei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oscar Moradei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oscar Moradei more than expected).

Fields of papers citing papers by Oscar Moradei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oscar Moradei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oscar Moradei. The network helps show where Oscar Moradei may publish in the future.

Co-authorship network of co-authors of Oscar Moradei

This figure shows the co-authorship network connecting the top 25 collaborators of Oscar Moradei. A scholar is included among the top collaborators of Oscar Moradei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oscar Moradei. Oscar Moradei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mitchell, Lorna H., Allison E. Drew, Scott Ribich, et al.. (2015). Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters. 6(6). 655–659. 95 indexed citations
2.
Boriack‐Sjodin, P. Ann, Lei Jin, Suzanne L. Jacques, et al.. (2015). Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates. ACS Chemical Biology. 11(3). 763–771. 32 indexed citations
3.
Boriack-Sjodin, Ann, Lei Jin, Suzanne L. Jacques, et al.. (2015). Abstract 2437: Crystal structures of CARM1 bound to sinefungin and diverse peptide substrates. Cancer Research. 75(15_Supplement). 2437–2437. 1 indexed citations
4.
Fournel, Marielle, Claire Bonfils, Yu Hou, et al.. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics. 7(4). 759–768. 271 indexed citations
5.
Moradei, Oscar, Arkadii Vaisburg, & Robert E. Martell. (2008). Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents. Current Topics in Medicinal Chemistry. 8(10). 841–858. 37 indexed citations
6.
Moradei, Oscar, Sylvie Fréchette, Isabelle Paquin, et al.. (2007). Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity. Journal of Medicinal Chemistry. 50(23). 5543–5546. 137 indexed citations
7.
8.
Moradei, Oscar, et al.. (2005). Rapid occurrence of sugar tricyclic orthoesters by acid catalyzed intramolecular orthotransesterification. ARKIVOC. 2005(12). 189–194. 5 indexed citations
9.
Moradei, Oscar, Christiane R. Maroun, Isabelle Paquin, & Arkadii Vaisburg. (2005). Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects. PubMed. 5(5). 529–560. 69 indexed citations
10.
Zhou, Nancy, Marielle Fournel, Daniel Delorme, et al.. (2004). 83 Antitumor activities of MGCD0103, a novel isotype-selective histone deacetylase inhibitor. European Journal of Cancer Supplements. 2(8). 28–28. 2 indexed citations
11.
Vaisburg, Arkadii, Naomy Bernstein, Sylvie Fréchette, et al.. (2003). (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(1). 283–287. 21 indexed citations
12.
Bouchain, Giliane, Silvana Leit, Sylvie Fréchette, et al.. (2003). Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry. 46(5). 820–830. 52 indexed citations
13.
Woo, Soon Hyung, Sylvie Fréchette, Giliane Bouchain, et al.. (2002). Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry. 45(13). 2877–2885. 53 indexed citations
14.
Bernardelli, Patrick, Oscar Moradei, Dirk Friedrich, et al.. (2001). Total Asymmetric Synthesis of the Putative Structure of the Cytotoxic Diterpenoid (−)-Sclerophytin A and of the Authentic Natural Sclerophytins A and B. Journal of the American Chemical Society. 123(37). 9021–9032. 86 indexed citations
15.
16.
17.
Moradei, Oscar, et al.. (1999). Catalytic Hydrogenation of Phosphate Enol Esters Present in Branched Chain Dienepyranosides in a Route to Thromboxane Analogs from D-Galactose. Journal of Carbohydrate Chemistry. 18(1). 15–29. 3 indexed citations
18.
Cirelli, Alicia Fernández, Oscar Moradei, & Joachim Thiem. (1997). Synthesis of Thromboxane A2 Models from Glucose. II. Epoxidation Studies of Hex‐2‐enopyranosides. Liebigs Annalen. 1997(9). 1983–1987. 2 indexed citations
19.
Moradei, Oscar, et al.. (1997). Anomalous Horner-Wadsworth-Emmons reactions on 3,4-enuloses. Tetrahedron. 53(22). 7397–7402. 4 indexed citations
20.
Moradei, Oscar, et al.. (1995). Simple Stereocontrolled Synthesis of Methyl 2-Deoxy-d-erythro-hexopyranosid-4-uloses, Thromboxane B2(TXB2) Precursors, fromd-Galactose. Journal of Carbohydrate Chemistry. 14(4-5). 525–532. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael F. T. Koehler Breakdown of academic impact, for papers by Peter Kovar Breakdown of academic impact, for papers by William C. Trenkle Breakdown of academic impact, for papers by Sukumar Sakamuri Breakdown of academic impact, for papers by Matthew G. Bursavich Breakdown of academic impact, for papers by Peter Lassota Breakdown of academic impact, for papers by Blaise Lippa Breakdown of academic impact, for papers by Ivo Zemp Breakdown of academic impact, for papers by Raul R. Calvo Breakdown of academic impact, for papers by Mary Pat Beavers
Rankless by CCL
2026